Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Medtronic and Arbor Surgical Technologies agree global licensing heart valve deal

Medtronic : 28 January, 2008  (New Product)
Medtronic and Arbor Surgical Technologies have made an exclusive global licensing agreement that will see Medtronic manufacture, market and distribute Arbor’s bovine pericardial tissue heart valve technologies.
Medtronic has acquired a minority stake in Arbor. Arbor has retained its exclusive rights to the modular Trilogy Aortic Valve System and sutureless TRE implantation technologies.

“We are optimistic that Arbor’s pericardial valve design combined with Medtronic’s proprietary technologies will achieve best-in-class performance. I am truly excited about this opportunity and the ongoing strengthening of our Structural Heart Disease product offering.” said Dr John Liddicoat, vice president and general manager of the Structural Heart Disease business at Medtronic, “No other comparable technology exists today.” Dr Thomas Fogarty, Arbor’s chairman and co-founder, added, “I am pleased to be partnering with a company like Medtronic that has the ability to bring our technology to so many patients.”

The technology will complement Medtronic’s Structural Heart Disease therapy objectives, which are focused on developing effective options for valve disease, septal defects and atrial fibrillation. Medtronic anticipates that development of Arbor's technology will enable future pericardial valves to achieve similar industry-leading patient survival outcomes as has been achieved with the Hancock II and third-generation Mosaic and Freestyle porcine valves. The company will continue to enhance its range of third-generation porcine valves, as well as invest in its transcatheter valve programme. Medtronic anticipates manufacturing the valve in its existing production facilities.

Valve inventor Ernie Lane, designer of multiple pericardial, created arbor’s heart valve technology valves currently on the market, to address several known failure modes exhibited in existing pericardial valve designs. “I was not satisfied with the durability of the existing pericardial valves and felt there to be room for improvement,” said Lane, Arbor’s co-founder. Arbor’s technology will stimulate the development of Medtronic’s first pericardial valve, which will complement its portfolio of porcine and mechanical heart valves.

According to the Millennium Research Group, more than 106,000 heart valves are expected to be implanted in the in the USA in 2008.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo